POU2F1 and neoplasm: we observed that POU2F1 silencing significantly enhanced the sensitivity of HCT116/L tumors to oxaliplatin by decreasing tumor sizes and weights (p < 0.05, p < 0.01, Figs. 7P–R and S10F), compared to HCT116/L tumors.